Date: 2014-07-22
Type of information: Grant
Company: Trianta Immunotherapies, a Medigene subsidiary (Germany)
Investors: German Research Foundation (DFG) (Germany)
Amount:
Funding type: grant
Planned used: The project of Trianta is an integral part of the consortium that includes other projects of acclaimed scientists from Charité Universitätsmedizin Berlin, the Max Delbrück Center for Molecular Medicine (MDC), Humboldt University of Berlin (HU), Ludwig Maximilian University of Munich (LMU), Munich University of Technology (TUM) and the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU). SFB-TR36 \"Principles and Applications of Adoptive T Cell Therapy\" is funded by the German Research Foundation with a focus on the development of effective approaches to combat cancer using adoptive T cell transfer. The SFB programme is set to run until 2018. Trianta\'s participation in SFB-TR36 secures established scientific and project-related cooperation with these leading German research institutions in the field of cancer immunotherapy. In particular, the promotion of technology transfer in a joint project with the HMGU facilitates access for Trianta to highly innovative preclinical tumour models for testing the efficacy of its own developed therapeutic concepts. Medigene AG/Trianta Immunotherapies GmbH has three highly innovative, complementary immunotherapy platforms. In the area of adoptive T cell therapy with T cell receptor-modified T cells, the company is working on the further development of a GMP-compliant manufacturing process and continuing preparations for the clinical development of the first product candidates.
Others: * On July 22, 2014, Medigene has announced that its subsidiary, Trianta Immunotherapies GmbH, will be an active project partner in the transregional Collaborative Research Centre (SFB-TR36) \"Principles and Applications of Adoptive T Cell Therapy\" of the German Research Foundation (DFG). The DFG will continue the funding phase of the SFB-TR36, started in 2006, for another four years.
Therapeutic area: Cancer - Oncology
